Clinical Trial Update: Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study (Lunsayil 1) evaluating spesolimab for hidradenitis suppurativa has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hidradenitis Suppurativa | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-11-05